Evidence map›Paper›PMID 29377283›Full record

ArticleJournal of leukocyte biology2018

Soluble CD14, CD163, and CD27 biomarkers distinguish ART-suppressed youth living with HIV from healthy controls.

Julie C Williams, Xinrui Zhang, Manju Karki, Yueh-Yun Chi, Shannon M Wallet, Bret J Rudy, Sharon L Nichols, Maureen M Goodenow, John W Sleasman

Open access · greenAbstract read
In one paragraph

Article in Journal of leukocyte biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 37 citations in OpenAlex.

  1. Trial
  2. Review
  3. Proteomic Characterization of HIV Infection.Advances in experimental medicine and biology · 2026
    Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Julie C WilliamsDepartment of Pathology, Immunology, and Laboratory Medicine, University of Florida, Gainesville, Florida, USA.
Xinrui ZhangDepartment of Biostatistics, University of Florida, Gainesville, Florida, USA.
Manju KarkiDepartment of Pathology, Immunology, and Laboratory Medicine, University of Florida, Gainesville, Florida, USA.
Yueh-Yun ChiDepartment of Biostatistics, University of Florida, Gainesville, Florida, USA.
Shannon M WalletDepartment of Oral Biology, College of Dentistry, University of Florida, Gainesville, Florida, USA.
Bret J RudyNew York University School of Medicine, New York, New York, USA.
Sharon L NicholsDepartment of Neurosciences, University of California, San Diego, La Jolla, California, USA.
Maureen M GoodenowDepartment of Pathology, Immunology, and Laboratory Medicine, University of Florida, Gainesville, Florida, USA.
John W SleasmanDepartment of Pediatrics, Division of Allergy, Immunology and Pulmonary Medicine, School of Medicine, Duke University, Durham, North Carolina, USA.
University of Florida · USDuke University · USNew York University · USUniversity of California, San Diego · US

Funding

Adol. Medicine Trials Network for HIV/AIDS InterventionsU01HD040474 · NICHD · WESTAT, INC. · PI HARRIS, DONALD ROBERT · 2001 to 2016
$114.4M
UCSF CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR024131 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHNSTON, S. CLAIBORNE · 2006 to 2011
$111.2M
International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) GroupU01AI068632 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI JACKSON, J BROOKS · 2006 to 2010
$109.7M
LEADERSHIP GROUP FOR ADOLESCENT MEDICINE TRIALS NETWORKU01HD040533 · NICHD · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI WILSON, CRAIG M · 2001 to 2016
$76.4M
INSTITUTIONAL CLINICAL AND TRANSLATIONAL SCIENCE AWARDUL1RR024134 · NCRR · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2006 to 2011
$70.4M
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR025780 · NCRR · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2008 to 2011
$61.3M
Social and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI GEORGIA Doris TOMARAS · 2005 to 2026
$50.5M
UVDM01RR010284 · NCRR · HOWARD UNIVERSITY · PI TAYLOR, ROBERT E. · 1996 to 2010
$17.4M
ZAP-70 EXPRESSION, CD38 EXPRESSION AND PROGNOSIS IN CHRONIC LYMPHOCYTIC LEUKEMIAM01RR020359 · NCRR · CHILDREN'S RESEARCH INSTITUTE · PI MIRZA, NAZRAT · 2005 to 2010
$13.8M
Substance Use and Immunity in HIV+ Adolescents by Systems BiologyR01DA031017 · NIDA · UNIVERSITY OF FLORIDA · PI YIN, LI · 2010 to 2014
$4.4M
Consequences of marijuana use on inflammatory pathways in HIV-infected youthU01DA044571 · NIDA · DUKE UNIVERSITY · PI SLEASMAN, JOHN W. · 2017 to 2021
$2.9M
NCRR NIH HHS M01 RR010284NCRR NIH HHS M01 RR020359NCRR NIH HHS UL1 RR024131NCRR NIH HHS UL1 RR024134NCRR NIH HHS UL1 RR025780NIAID NIH HHS P30 AI064518NIAID NIH HHS U01 AI068632NICHD NIH HHS U01 HD040474NICHD NIH HHS U01 HD040533NIDA NIH HHS R01 DA031017NIDA NIH HHS U01 DA044571
6 · The paper itself

Abstract

objectiveTo define inflammatory pathways in youth living with HIV infection (YLWH), assessments of biomarkers associated with lymphocyte and macrophage activation, vascular injury, or bone metabolism were performed in YLWH in comparison with healthy controls (HC).

designLongitudinal multicenter study comparing biomarkers in YLWH suppressed on antiretroviral therapy (ART), those with ongoing viral replication, and HC were compared using single blood samples obtained at end of study.

methodsTwenty-three plasma proteins were measured by ELISA or multiplex assays. Principal component analysis (PCA) was used to define contributions of individual biomarkers to define outcome groups.

resultsThe study cohort included 129 predominantly African American, male participants, 21-25 years old at entry. Nine biomarkers of lymphocyte and macrophage activation and cardiovascular injury differed between HC and YLWH. Significant positive correlations were identified between lymphocyte and macrophage activation biomarkers among HC and YLWH. Correlations distinct to YLWH were predominantly between biomarkers of macrophage and vascular inflammation. PCA of outcome groups showed HC and suppressed YLWH clustering together for lymphocyte activation biomarkers, whereas macrophage activation markers showed all YLWH clustering distinct from HC. Cardiovascular biomarkers were indistinguishable across groups. Averaged variable importance projection to assess single biomarkers that maximally contribute to discriminate among outcome groups identified soluble CD27, CD14, and CD163 as the 3 most important with TNFα and LPS also highly relevant in providing separation.

conclusionsSoluble inflammatory and lymphocyte biomarkers sufficiently distinguish YLWH from HC. Persistent macrophage activation biomarkers may provide a means to monitor consequences of HIV infection in fully suppressed YLWH.

Indexed as

Antiretroviral Therapy, Highly ActiveAdultAntigens, CDAntigens, Differentiation, MyelomonocyticBiomarkersCase-Control StudiesCD163 AntigenFemaleHIVHIV InfectionsHumansLipopolysaccharide ReceptorsLongitudinal StudiesLymphocyte ActivationMacrophage ActivationMaleAntigens, CDAntigens, Differentiation, MyelomonocyticBiomarkersCD163 AntigenLipopolysaccharide ReceptorsReceptors, Cell SurfaceTumor Necrosis Factor Receptor Superfamily, Member 7adolescentsbiomarkerchemokinescytokinesHIVinflammationlymphocytesmacrophage

Identifiers

PMID29377283
PMCPMC6528780
OpenAlexW2789396131

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.